Research programme: Interleukin 4 receptor alpha subunit targeting therapeutics - Generian Pharmaceuticals
Latest Information Update: 12 Jul 2024
At a glance
- Originator Generian Pharmaceuticals
- Class Small molecules
- Mechanism of Action Interleukin 4 receptor alpha subunit modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 01 Jul 2024 Early research in Unspecified in USA (PO) prior to June 2024 (Generian Pharmaceuticals Pipeline, June 2024)